PMID- 24664767
OWN - NLM
STAT- MEDLINE
DCOM- 20140724
LR  - 20211203
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 801
DP  - 2014
TI  - Nipradilol promotes axon regeneration through S-nitrosylation of PTEN in retinal 
      ganglion cells.
PG  - 751-7
LID - 10.1007/978-1-4614-3209-8_94 [doi]
AB  - Nipradilol (Nip) is registered as an anti-glaucoma agent. More recently, a 
      protective effect of Nip has been demonstrated in retinal ganglion cells (RGCs) 
      mediated by S-nitrosylation of antioxidative-related Keap1 protein due to its 
      nitric oxide (NO)-donating effect. It also has been reported that Nip promoted 
      axon outgrowth in cat RGCs. However, the detailed mechanism remains unclear. NO 
      physiologically regulates numerous cellular responses through S-nitrosylation of 
      protein at cysteine residues. It has been reported that phosphatase and tensin 
      homologue deleted on chromosome 10 (PTEN) deletion strongly showed axon 
      regeneration after optic nerve injury. PTEN inactivation by S-nitrosylation 
      results in the accumulation of phosphatidylinositol (3, 4, 5) triphosphate (PIP3) 
      and the activation of Akt/mammalian target of rapamycin (mTOR) signaling. The 
      ribosomal S6 kinase 1 (S6K) which can monitor as phospho-S6 (pS6) is one of major 
      target of mTOR. In this study, we investigated the possibility that Nip can 
      promote axon outgrowth in RGCs by Akt/mTOR signaling thorough S-nitrosylation of 
      PTEN.
FAU - Koriyama, Yoshiki
AU  - Koriyama Y
AD  - Department of Molecular Neurobiology, Graduate School of Medicine, Kanazawa 
      University, 13-1 Takaramachi, 920-8640, Kanazawa, Japan, 
      koriyama@med.kanazawa-u.ac.jp.
FAU - Kamiya, Marie
AU  - Kamiya M
FAU - Arai, Kunizo
AU  - Arai K
FAU - Sugitani, Kayo
AU  - Sugitani K
FAU - Ogai, Kazuhiro
AU  - Ogai K
FAU - Kato, Satoru
AU  - Kato S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Propanolamines)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 2.7.1.1 (mTOR protein, mouse)
RN  - EC 2.7.11.1 (Akt1 protein, mouse)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (Pten protein, mouse)
RN  - FVM336I71Y (nipradilol)
SB  - IM
MH  - Adrenergic beta-Antagonists/pharmacology
MH  - Animals
MH  - Cell Line, Transformed
MH  - Glaucoma/*drug therapy
MH  - Mice
MH  - Nerve Regeneration/*drug effects/physiology
MH  - Nitric Oxide/*metabolism
MH  - PTEN Phosphohydrolase/*metabolism
MH  - Propanolamines/*pharmacology
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Rats
MH  - Retinal Ganglion Cells/cytology/drug effects/*physiology
MH  - Signal Transduction/drug effects/physiology
MH  - TOR Serine-Threonine Kinases/metabolism
EDAT- 2014/03/26 06:00
MHDA- 2014/07/25 06:00
CRDT- 2014/03/26 06:00
PHST- 2014/03/26 06:00 [entrez]
PHST- 2014/03/26 06:00 [pubmed]
PHST- 2014/07/25 06:00 [medline]
AID - 10.1007/978-1-4614-3209-8_94 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2014;801:751-7. doi: 10.1007/978-1-4614-3209-8_94.